文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

住院COVID-19患者凝血病:治疗性抗凝与标准护理的实用随机对照试验(RAPID COVID COAG - RAPID试验):随机对照试验研究方案的结构化摘要

Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2021-03-10

本研究为开放标签、平行、1:1、III期、双臂随机对照试验,旨在评估治疗性抗凝(低分子肝素或普通肝素高剂量诺模图)对比标准护理,对因COVID-19住院且D-二聚体升高的患者28天内复合结局(入住ICU、无创正压通气、有创机械通气或死亡)的影响。计划纳入462例患者(每组231例),以检测15%的风险差异(对照组50%至实验组35%),把握度90%,双侧α=0.05。

要点

  • 治疗性抗凝可能降低住院COVID-19伴D-二聚体升高患者的复合不良结局风险。
  • 试验计划纳入462例,对照组复合结局假设为50%,实验组为35%。
  • 主要复合结局包括入住ICU、无创正压通气、有创机械通气或死亡(28天内)。

核心结论

  • 评估治疗性抗凝对比标准护理对住院COVID-19伴D-二聚体升高患者28天复合结局的影响。

研究设计与样本

  • 开放标签、平行、1:1、III期、双臂随机对照试验,计划纳入462例(每组231例)。
  • 纳入标准包括实验室确诊COVID-19、D-二聚体高于正常上限且满足特定条件、年龄>18岁等。
  • 排除标准包括妊娠、血红蛋白<80 g/L、血小板<50 x 10^9/L、已知纤维蛋白原<1.5 g/L、INR>1.8等。
  • 随机化按中心和年龄(>65岁 vs ≤65岁)分层,使用1:1计算机生成随机分配序列,可变区组大小。

主要发现

  • 主要复合结局为28天内入住ICU、无创正压通气、有创机械通气或死亡。
  • 次要结局包括全因死亡、大出血(ISTH-SSC定义)、输血、肾脏替代治疗、无住院天数等。

关键数值与推荐

  • 样本量462例(每组231例)可检测15%风险差异(对照组50%至实验组35%),把握度90%,双侧α=0.05。
  • 纳入要求D-二聚体高于正常上限(ULN)且满足以下之一:D-二聚体≥2倍ULN,或D-二聚体>ULN且室内空气血氧饱和度≤93%。

临床怎么用

  • 对于住院COVID-19伴D-二聚体升高且未达危重期的成人患者,可考虑治疗性抗凝,但需权衡出血风险。
  • 治疗性抗凝可选低分子肝素或普通肝素高剂量诺模图,具体由临床医生根据当地供应决定。

局限性

  • 开放标签设计可能引入偏倚。
  • 试验排除了高出血风险、已抗凝、已入住ICU或已使用机械通气的患者,结果外推受限。
  • 样本量基于假设的15%风险差异,实际效应可能不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the effect of therapeutic anticoagulation, with low molecular weight heparin (LMWH) or unfractionated heparin (UFH, high dose nomogram), compared to standard care in hospitalized patients admitted for COVID-19 with an elevated D-dimer on the composite outcome of intensive care unit (ICU) admission, non-invasive positive pressure ventilation, invasive mechanical ventilation or death up to 28 days. TRIAL DESIGN: Open-label, parallel, 1:1, phase 3, 2-arm randomized controlled trial PARTICIPANTS: The study population includes hospitalized adults admitted for COVID-19 prior to the development of critical illness. Excluded individuals are those where the bleeding risk or risk of transfusion would generally be considered unacceptable, those already therapeutically anticoagulated and those who have already have any component of the primary composite outcome. Participants are recruited from hospital sites in Brazil, Canada, Ireland, Saudi Arabia, United Arab Emirates, and the United States of America. The inclusion criteria are: 1) Laboratory confirmed COVID-19 (diagnosis of SARS-CoV-2 via reverse transcriptase polymerase chain reaction as per the World Health Organization protocol or by nucleic acid based isothermal amplification) prior to hospital admission OR within first 5 days (i.e. 120 hours) after hospital admission; 2) Admitted to hospital for COVID-19; 3) One D-dimer value above the upper limit of normal (ULN) (within 5 days (i.e. 120 hours) of hospital admission) AND EITHER: a. D-Dimer ≥2 times ULN OR b. D-Dimer above ULN and Oxygen saturation ≤ 93% on room air; 4) > 18 years of age; 5) Informed consent from the patient (or legally authorized substitute decision maker). The exclusion criteria are: 1) pregnancy; 2) hemoglobin <80 g/L in the last 72 hours; 3) platelet count <50 x 109/L in the last 72 hours; 4) known fibrinogen <1.5 g/L (if testing deemed clinically indicated by the treating physician prior to the initiation of anticoagulation); 5) known INR >1.8 (if testing deemed clinically indicated by the treating physician prior to the initiation of anticoagulation); 6) patient already prescribed intermediate dosing of LMWH that cannot be changed (determination of what constitutes an intermediate dose is to be at the discretion of the treating clinician taking the local institutional thromboprophylaxis protocol for high risk patients into consideration); 7) patient already prescribed therapeutic anticoagulation at the time of screening [low or high dose nomogram UFH, LMWH, warfarin, direct oral anticoagulant (any dose of dabigatran, apixaban, rivaroxaban, edoxaban)]; 8) patient prescribed dual antiplatelet therapy, when one of the agents cannot be stopped safely; 9) known bleeding within the last 30 days requiring emergency room presentation or hospitalization; 10) known history of a bleeding disorder of an inherited or active acquired bleeding disorder; 11) known history of heparin-induced thrombocytopenia; 12) known allergy to UFH or LMWH; 13) admitted to the intensive care unit at the time of screening; 14) treated with non-invasive positive pressure ventilation or invasive mechanical ventilation at the time of screening; 15) Imminent death according to the judgement of the most responsible physician; 16) enrollment in another clinical trial of antithrombotic therapy involving hospitalized patients. INTERVENTION AND COMPARATOR: Intervention: Therapeutic dose of LMWH (dalteparin, enoxaparin, tinzaparin) or high dose nomogram of UFH. The choice of LMWH versus UFH will be at the clinician's discretion and dependent on local institutional supply. Comparator: Standard care [thromboprophylactic doses of LMWH (dalteparin, enoxaparin, tinzaparin, fondaparinux)] or UFH. Administration of LMWH, UFH or fondaparinux at thromboprophylactic doses for acutely ill hospitalized medical patients, in the absence of contraindication, is generally considered standard care. MAIN OUTCOMES: The primary composite outcome of ICU admission, non-invasive positive pressure ventilation, invasive mechanical ventilation or death at 28 days. Secondary outcomes include (evaluated up to day 28): 1. All-cause death 2. Composite of ICU admission or all-cause death 3. Composite of mechanical ventilation or all-cause death 4. Major bleeding as defined by the ISTH Scientific and Standardization Committee (ISTH-SSC) recommendation; 5. Red blood cell transfusion (>1 unit); 6. Transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate; 7. Renal replacement therapy; 8. Hospital-free days alive; 9. ICU-free days alive; 10. Ventilator-free days alive; 11. Organ support-free days alive; 12. Venous thromboembolism (defined as symptomatic or incidental, suspected or confirmed via diagnostic imaging and/or electrocardiogram where appropriate); 13. Arterial thromboembolism (defined as suspected or confirmed via diagnostic imaging and/or electrocardiogram where appropriate); 14. Heparin induced thrombocytopenia; 15. Trajectories of COVID-19 disease-related coagulation and inflammatory biomarkers. RANDOMISATION: Randomisation will be stratified by site and age (>65 versus ≤65 years) using a 1:1 computer-generated random allocation sequence with variable block sizes. Randomization will occur within the first 5 days (i.e. 120 hours) of participant hospital admission. However, it is recommended that randomization occurs as early as possible after hospital admission. Central randomization using an interactive web response system will ensure allocation concealment. BLINDING (MASKING): No blinding involved. This is an open-label trial. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): 462 patients (231 per group) are needed to detect a 15% risk difference, from 50% in the control group to 35% in the experimental group, with power of 90% at a two-sided alpha of 0.05. TRIAL STATUS: Protocol Version Number 1.4. Recruitment began on May 11th, 2020. Recruitment is expected to be completed March 2022. Recruitment is ongoing. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04362085 Date of Trial Registration: April 24, 2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sholzberg M, Tang GH, Negri E, et al. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial. Trials. 2021. PMID: 33691765. doi:10.1186/s13063-021-05076-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。